Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

ABSTRACT:

Background

Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD.

Methods

In this retrospective study, we identified 1088 patients with grade I-IIIA FL; of whom, 238 patients with stage II-IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PE

SUBMITTER: Batlevi CL 

PROVIDER: S-EPMC7331469 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature